Andra AP fonden Takes Position in Axon Enterprise, Inc. (NASDAQ:AXON)

Andra AP fonden purchased a new stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The fund purchased 21,500 shares of the biotechnology company's stock, valued at approximately $6,326,000.

A number of other hedge funds have also added to or reduced their stakes in AXON. Norges Bank acquired a new position in Axon Enterprise during the 4th quarter valued at about $195,406,000. Motley Fool Asset Management LLC boosted its stake in shares of Axon Enterprise by 238.7% in the 1st quarter. Motley Fool Asset Management LLC now owns 492,140 shares of the biotechnology company's stock worth $153,981,000 after buying an additional 346,838 shares during the last quarter. 1832 Asset Management L.P. purchased a new position in shares of Axon Enterprise in the 1st quarter worth approximately $81,630,000. Vanguard Group Inc. boosted its stake in shares of Axon Enterprise by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 8,143,306 shares of the biotechnology company's stock worth $2,547,878,000 after buying an additional 212,401 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Axon Enterprise by 110.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 276,011 shares of the biotechnology company's stock worth $71,302,000 after buying an additional 144,568 shares during the last quarter. Institutional investors and hedge funds own 79.08% of the company's stock.

Insiders Place Their Bets

In other Axon Enterprise news, CFO Brittany Bagley sold 4,338 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $378.95, for a total transaction of $1,643,885.10. Following the sale, the chief financial officer now owns 98,825 shares in the company, valued at $37,449,733.75. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Axon Enterprise news, CFO Brittany Bagley sold 4,338 shares of the firm's stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $378.95, for a total value of $1,643,885.10. Following the sale, the chief financial officer now owns 98,825 shares of the company's stock, valued at approximately $37,449,733.75. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the business's stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $373.03, for a total value of $167,863.50. Following the transaction, the director now directly owns 7,379 shares of the company's stock, valued at approximately $2,752,588.37. The disclosure for this sale can be found here. Insiders have sold a total of 316,981 shares of company stock worth $115,281,744 over the last 90 days. Corporate insiders own 6.10% of the company's stock.

Axon Enterprise Stock Performance

Shares of NASDAQ:AXON traded up $22.80 during trading on Thursday, hitting $384.51. 973,638 shares of the company were exchanged, compared to its average volume of 520,782. The company has a market cap of $29.02 billion, a PE ratio of 111.49, a P/E/G ratio of 9.50 and a beta of 0.94. The stock has a 50 day moving average of $335.53 and a 200 day moving average of $313.10. Axon Enterprise, Inc. has a 52-week low of $189.12 and a 52-week high of $384.73. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.18. The firm had revenue of $504.00 million for the quarter, compared to the consensus estimate of $478.35 million. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The business's quarterly revenue was up 34.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.80 earnings per share. As a group, equities research analysts predict that Axon Enterprise, Inc. will post 1.79 EPS for the current year.

Wall Street Analysts Forecast Growth

AXON has been the topic of a number of research analyst reports. Robert W. Baird boosted their target price on Axon Enterprise from $360.00 to $400.00 and gave the stock an "outperform" rating in a research note on Tuesday. Needham & Company LLC restated a "buy" rating and issued a $400.00 target price on shares of Axon Enterprise in a research note on Wednesday, August 7th. JMP Securities boosted their target price on Axon Enterprise from $375.00 to $430.00 and gave the stock an "outperform" rating in a research note on Thursday. Bank of America initiated coverage on Axon Enterprise in a research note on Wednesday, July 17th. They issued a "buy" rating and a $380.00 target price on the stock. Finally, Craig Hallum lifted their price target on shares of Axon Enterprise from $370.00 to $376.00 and gave the stock a "buy" rating in a report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, Axon Enterprise presently has an average rating of "Moderate Buy" and an average price target of $365.38.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.